论文部分内容阅读
上海生物制品研究所于1969年起开展了甲_2巨球蛋白的研制工作,随后和上海市工业卫生研究所共同协作,组织了临床疗效的考核,后又在上海肿瘤医院、上海国际和平妇幼保健院的协作下,对该制剂进行3种疗效观察:(1)放疗部位手术切口坏死崩裂,经常规处理难愈者;(2)宫颈癌放疗后,放射性直肠炎伴有粘膜溃疡出血,经常规止血、抗炎治疗未见效者;(3)急、慢性放射性皮肤粘膜坏死溃疡,
Shanghai Institute of Biological Products began work on the development of alpha-2 macroglobulin in 1969. Later, it collaborated with the Shanghai Institute of Industrial Hygiene to organize the assessment of clinical efficacy, and later at Shanghai Cancer Hospital, Shanghai International Peace and Women’s Hospital. Under the cooperation of the hospital, three therapeutic effects were observed for the preparation: (1) necrosis and cracking of the surgical incision at the radiotherapy site, which were refractory to conventional treatment; (2) radiotherapy proctitis with mucosal ulcer bleeding after radiotherapy for cervical cancer. Routine hemostasis and anti-inflammatory treatment are not effective; (3) acute and chronic radioactive skin mucosal necrosis ulcers,